Pure Global
NCT06317701

Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation

Hgns: Metabolic Endpoints For Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation
University of Chicago·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Obstructive Sleep Apnea
Drug/Device/Intervention
Hypoglossal Nerve Stimulation (HGNS)
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
University of Chicago
Location
Chicago, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 04, 2024
End date
Apr 01, 2028
Enrollment
30 participants
Primary outcome

Glycemic variability,Mean systolic BP (daytime and nocturnal),Glycemic variability

Summary

The purpose of this study is to determine if the treatment of Obstructive sleep apnea (OSA)
 by hypoglossal nerve stimulation (HGNS) will alter glucose metabolism. The study team will
 also determine if the treatment of Obstructive sleep apnea (OSA) by (hypoglossal nerve
 stimulation) HGNS will alter predictors of cardiovascular outcomes.

ICD-10 classifications
Sleep apnoeaSleep disordersSleep disorder, unspecifiedPrimary sleep apnoea of newbornNonorganic sleep disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06317701
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06317701 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Chicago and is currently Recruiting. The study focuses on Obstructive Sleep Apnea. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.